April 09, 2025 | Katie Ghiardi
Registration Now Open for June 7 Event in Maple Lawn Howard County
Participants can choose between the 13.1-mile half marathon and the 5K race/walk. Registration is $75 for the half marathon and $40 for the 5K through Thursday, June 5; fees increase on Friday, June 6, when registration closes at 9 p.m. All registered runners and walkers receive an official race T-shirt, medal, and access to a personalized training and fundraising dashboard.
“Each year, it’s incredible to witness how participants, volunteers, and donors unite to bring hope to those battling cancer,” said Michael Greenebaum, co-founder of the Maryland Half Marathon & 5K and a UMGCCC Board of Advisors member. “Through our collective efforts, we continue to push the boundaries of research and care, moving us closer to a future free from this disease.”
Race participants can use the free Good Move app to track their training miles, invite friends to donate, and stay motivated throughout their fundraising journey. Individuals who prefer not to run or walk can register free as fundraisers—with a minimum $5 self-donation required to access all fundraising tools—ensuring everyone can support the event’s $500,000 fundraising goal.
For more information or to register, visit www.mdhalfmarathon5k.org. Proceeds benefit research and patient programs at UMGCCC, where expert teams work tirelessly to advance cancer treatment from the laboratory to the bedside.
This year’s event is made possible by the support of St. John Properties, Greenebaum Enterprises, Berkeley Research Group, LLC, Chesapeake Contracting Group, and a team of dedicated volunteers and participants. To learn more about UMGCCC, visit www.umgccc.org.
About UMGCCC
UMGCCC is one of two NCI-designated comprehensive cancer centers in Maryland and one of 57 in the United States. It offers innovative approaches to diagnosing and treating all types of cancer, conducts cutting-edge research to bring the latest advances in cancer treatment directly to patients and provides cancer screening and patient education services. The cancer center is nationally recognized for its excellence in patient care and multidisciplinary, translational research programs.
In recent years, UMGCCC has pioneered advances in cancer treatment, including:
- Development of aromatase inhibitors to treat breast cancer by the late Angela Brodie, PhD
- Invention of the GammaPod, a new radiation treatment option for early-stage breast cancer that can reduce the number of treatments and spare healthy tissue from radiation
- Development of promising new drug compounds and immunotherapies, such as a next-generation chimeric antigen receptor (CAR) T-cell therapy.
Contact
Katie Ghiardi
Lead Media & Public Relations Specialist
University of Maryland Marlene and Stewart Greenebaum
Comprehensive Cancer Center
KGhiardi@som.umaryland.edu
Related stories

Wednesday, February 26, 2025
Innovative CT Scan Technique Could Improve Prognosis and Treatments for Head and Neck Cancers, New Research Suggests
Cancers occurring in the mouth, nose, and throat are on the rise in the U.S., especially in younger people. About 60,000 new cases are diagnosed every year with one in five cases occurring in people younger than 55, according to the American Cancer Society. A new study provides insights that may eventually help oncologists better predict how the disease will respond to certain therapies, leading to improved survival outcomes for patients.

Wednesday, December 04, 2024
Business Leader and Philanthropist Michael Greenebaum Named New Chair of the University of Maryland School of Medicine's Board of Visitors
University of Maryland School of Medicine (UMSOM) Dean Mark T. Gladwin, MD, has announced that prominent business leader and philanthropist Michael Greenebaum has been named Chair of the School's Board of Visitors. Mr. Greenebaum served as the Inaugural Vice Chair of the Board of Visitors since 2021 and has been a board member since 2012.

Thursday, July 15, 2021
University of Maryland Greenebaum Comprehensive Cancer Center Earns Renewal of Highest Designation for Cancer Center Excellence from National Cancer Institute
The University of Maryland Marlene and Stewart Greenebaum Comprehensive Cancer Center (UMGCCC) has earned renewal of its National Cancer Institute (NCI) designation as a Comprehensive Cancer Center for another five years. The prestigious distinction recognizes the cancer center’s high caliber of scientific leadership and robust programs in basic, clinical and population science research, placing it in the top echelon of cancer centers nationwide.